Astria Therapeutics, Inc. (NASDAQ:ATXS) Short Interest Up 25.7% in January

Astria Therapeutics, Inc. (NASDAQ:ATXS) was the recipient of a significant increase in short interest in January. As of January 15th, there was short interest totalling 3,370,000 shares, an increase of 25.7% from the December 31st total of 2,680,000 shares. Based on an average daily trading volume, of 286,800 shares, the short-interest ratio is presently 11.8 days. Approximately 7.4% of the company’s shares are sold short.

Hedge Funds Weigh In On Astria Therapeutics

A number of hedge funds have recently bought and sold shares of the company. Quest Partners LLC lifted its holdings in Astria Therapeutics by 180.8% during the 3rd quarter. Quest Partners LLC now owns 9,004 shares of the biotechnology company’s stock worth $99,000 after buying an additional 5,798 shares during the last quarter. China Universal Asset Management Co. Ltd. acquired a new position in Astria Therapeutics in the fourth quarter worth $107,000. PDT Partners LLC bought a new stake in Astria Therapeutics during the third quarter valued at $140,000. SG Americas Securities LLC acquired a new stake in shares of Astria Therapeutics during the third quarter worth $155,000. Finally, Hsbc Holdings PLC bought a new position in Astria Therapeutics in the second quarter worth about $171,000. 98.98% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms recently weighed in on ATXS. HC Wainwright restated a “buy” rating and set a $16.00 target price on shares of Astria Therapeutics in a report on Thursday, January 23rd. Oppenheimer raised their target price on Astria Therapeutics from $26.00 to $28.00 and gave the company an “outperform” rating in a report on Thursday, November 14th. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $25.60.

Astria Therapeutics Stock Performance

Shares of NASDAQ:ATXS traded up $0.03 during trading on Thursday, hitting $7.49. The company’s stock had a trading volume of 213,482 shares, compared to its average volume of 301,162. The company has a market capitalization of $422.66 million, a PE ratio of -3.58 and a beta of 0.70. The stock’s 50-day moving average price is $9.00 and its two-hundred day moving average price is $10.49. Astria Therapeutics has a fifty-two week low of $7.16 and a fifty-two week high of $16.90.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.